TaiMed Biologics Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	839.47	580.23	251.01	274.11	551.62	572.09
Short-Term Investments	924.91	1,072	395.49	309.93	406.68	629
Trading Asset Securities	-	-	-	58.75	-	-
Cash & Short-Term Investments	1,764	1,652	646.5	642.79	958.3	1,201
Cash Growth	-18.80%	155.58%	0.58%	-32.92%	-20.21%	-5.57%
Accounts Receivable	90.92	103.02	160.49	98.24	157.78	268.92
Other Receivables	33.99	31.3	28.16	25.49	35.41	19.69
Receivables	124.9	134.31	188.65	123.73	193.19	288.61
Inventory	1,408	1,569	1,271	1,389	1,177	1,281
Prepaid Expenses	5.6	6.41	10.01	4.15	3.54	4.73
Other Current Assets	6.11	31.16	35.63	5.08	2.59	2.93
Total Current Assets	3,309	3,394	2,151	2,165	2,335	2,778
Property, Plant & Equipment	821.21	857.4	908.26	957.74	1,011	1,065
Long-Term Investments	15.22	-	0.9	43.44	232.63	203
Other Intangible Assets	466.17	539.4	625.79	724.38	821.33	940.16
Other Long-Term Assets	206.77	208.79	207.58	210.57	211.19	210.59
Total Assets	4,819	4,999	3,894	4,101	4,611	5,196
Accounts Payable	4.34	0.76	13.5	0.09	122.58	6.16
Accrued Expenses	4.6	11.63	7.49	39.39	51.64	361.04
Short-Term Debt	-	-	200	200	-	-
Current Portion of Long-Term Debt	27.69	27.24	26.97	14.32	-	-
Current Portion of Leases	2.28	2.26	2.18	2.02	1.95	1.93
Current Unearned Revenue	112.63	74.32	91.12	57.48	24.34	37.59
Other Current Liabilities	24.15	18.56	19.92	16.57	24.57	54.81
Total Current Liabilities	175.69	134.77	361.17	329.86	225.08	461.52
Long-Term Debt	447.2	468.03	495.04	521.68	536	536
Long-Term Leases	23.38	25.1	26.67	28.12	29.38	31.32
Long-Term Unearned Revenue	250.46	347.53	444.04	505.6	877.9	750.74
Other Long-Term Liabilities	-	0.92	0.92	0.92	0.87	0.86
Total Liabilities	896.74	976.34	1,328	1,386	1,669	1,780
Common Stock	2,732	2,731	2,530	2,526	2,523	2,522
Additional Paid-In Capital	2,467	2,452	986.67	945.45	925.14	4,832
Retained Earnings	-1,236	-1,136	-934.56	-740.22	-470.93	-3,921
Comprehensive Income & Other	-41.01	-23.89	-16.13	-15.83	-35.97	-17.6
Shareholders' Equity	3,922	4,023	2,566	2,715	2,942	3,416
Total Liabilities & Equity	4,819	4,999	3,894	4,101	4,611	5,196
Total Debt	500.56	522.63	750.86	766.14	567.32	569.25
Net Cash (Debt)	1,264	1,130	-104.35	-123.35	390.98	631.84
Net Cash Growth	-23.07%	-	-	-	-38.12%	-48.96%
Net Cash Per Share	4.63	4.21	-0.41	-0.49	1.55	2.51
Filing Date Shares Outstanding	273.2	273.08	253.01	252.55	252.33	252.22
Total Common Shares Outstanding	273.2	273.08	253.01	252.55	252.33	252.22
Working Capital	3,134	3,259	1,790	1,835	2,110	2,316
Book Value Per Share	14.36	14.73	10.14	10.75	11.66	13.54
Tangible Book Value	3,456	3,484	1,940	1,991	2,120	2,476
Tangible Book Value Per Share	12.65	12.76	7.67	7.88	8.40	9.82
Land	194.61	194.61	194.61	194.61	194.61	194.61
Buildings	497.83	495.41	493.95	493.54	493.12	492.72
Machinery	458.71	457.35	455.56	450.03	446.9	443.66
Leasehold Improvements	4.64	4.64	4.64	4.64	4.64	4.64

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.